Abstract
Background. Multidrug-resistant Acinetobacter baumannii infections are considered a serious threat by the Centers for Disease Control and other government agencies. They are among the most difficult to treat and are associated with high mortality rates due to the limited number of effective therapies available and inappropriate initial treatment choice. The novel diazabicyclooctenone β-lactamase inhibitor effectively restores the antibacterial activity of sulbactam against multidrug-resistant (MDR) A. baumannii due to its potent inhibition of class A, C, and D serine β-lactamases, which are commonly found in this organism.